Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 190
Filter
1.
J Clin Microbiol ; 57(1)2019 01.
Article in English | MEDLINE | ID: mdl-30257900

ABSTRACT

The first World Health Organization (WHO) international standards (ISs) for nucleic acid amplification techniques were established two decades ago, with the initial focus on blood screening for three major viral targets, i.e., hepatitis C virus, hepatitis B virus, and human immunodeficiency virus 1. These reference materials have subsequently found utility in the diagnosis and monitoring of a wide range of infectious diseases in clinical microbiology laboratories worldwide. WHO collaborating centers develop ISs and coordinate international studies for their evaluation. The WHO Expert Committee on Biological Standardization is responsible for the endorsement of new standardization projects and the establishment of new and replacement ISs. Potencies of ISs are defined in international units (IU); the reporting in IU for assays calibrated with an IS (or secondary standards traceable to the IS) facilitates comparability of results for different assays and determination of assay parameters such as analytical sensitivities.


Subject(s)
Laboratories/standards , Nucleic Acid Amplification Techniques/standards , World Health Organization , Humans , International Cooperation , Nucleic Acids/chemistry , Nucleic Acids/genetics , Reference Standards
3.
Vet Comp Oncol ; 15(4): 1513-1526, 2017 Dec.
Article in English | MEDLINE | ID: mdl-28150446

ABSTRACT

The modified Glasgow Prognostic Score (mGPS) assigns a numerical value (0-2) from pre-treatment serum concentrations of C-reactive protein (CRP) and albumin to predict patient outcome. CRP and albumin were evaluated in 77 untreated dogs with lymphoma to determine the relationship of mGPS to clinicopathological parameters and whether it could predict progression-free (PFS) and overall survival (OS) in treated dogs. mGPS distribution was significantly associated with clinical stage, substage b, weight loss, gastrointestinal disturbances and lethargy at presentation. On univariate analysis, mGPS was significantly associated with OS and PFS, with shorter median survival times for mGPS 2 compared to mGPS 0 and 1 combined. Hypoalbuminaemia significantly reduced OS and PFS, however increased CRP had no effect. Only clinical stage was significantly associated with OS and PFS on both univariate and multivariate analysis. mGPS has potential prognostic value for canine lymphoma , but further studies are needed.


Subject(s)
Dog Diseases/diagnosis , Lymphoma/veterinary , Animals , C-Reactive Protein/analysis , Dog Diseases/mortality , Dog Diseases/pathology , Dogs , Female , Lymphoma/diagnosis , Lymphoma/mortality , Lymphoma/pathology , Male , Prognosis , Severity of Illness Index
4.
Article in English | MEDLINE | ID: mdl-26234803

ABSTRACT

Spatial navigation requires a well-established network of brain regions, including the hippocampus, caudate nucleus, and retrosplenial cortex. Amnestic Mild Cognitive Impairment (aMCI) is a condition with predominantly memory impairment, conferring a high predictive risk factor for dementia. aMCI is associated with hippocampal atrophy and subtle deficits in spatial navigation. We present the first use of a functional Magnetic Resonance Imaging (fMRI) navigation task in aMCI, using a virtual reality analog of the Radial Arm Maze. Compared with controls, aMCI patients showed reduced activity in the hippocampus bilaterally, retrosplenial cortex, and left dorsolateral prefrontal cortex. Reduced activation in key areas for successful navigation, as well as additional regions, was found alongside relatively normal task performance. Results also revealed increased activity in the right dorsolateral prefrontal cortex in aMCI patients, which may reflect compensation for reduced activations elsewhere. These data support suggestions that fMRI spatial navigation tasks may be useful for staging of progression in MCI.


Subject(s)
Amnesia/physiopathology , Brain/physiopathology , Cognitive Dysfunction/physiopathology , Spatial Navigation/physiology , User-Computer Interface , Aged , Aged, 80 and over , Brain Mapping , Female , Humans , Magnetic Resonance Imaging , Male , Neuropsychological Tests
5.
Article in English | MEDLINE | ID: mdl-24617815

ABSTRACT

Patients with amnestic mild cognitive impairment (aMCI) show preserved or mildly impaired working memory, despite their deficits in episodic memory. We aimed to identify performance and/or neural differences between aMCI patients and matched controls on a standard working memory fMRI task. Neuropsychological assessment demonstrated aMCI impairments in verbal and visual episodic long-term memory, with intact IQ and executive function. Participants completed a standard three-level N-back task where patients were unimpaired. Functional activations in the control group were found in expected areas, including the inferior parietal lobule and dorsolateral prefrontal cortex. Group differences were found in the insula and lingual gyrus and, in a region of interest analysis, in the hippocampus. In all cases, these were caused by an absence of task-related deactivations in the aMCI group. The results are consistent with reports of failure in task-related deacivations in aMCI and could be early indications of pathology.


Subject(s)
Brain/pathology , Cognitive Dysfunction/complications , Cognitive Dysfunction/pathology , Memory Disorders/etiology , Memory, Short-Term/physiology , Aged , Analysis of Variance , Brain/blood supply , Brain Mapping , Executive Function , Female , Humans , Image Processing, Computer-Assisted , Magnetic Resonance Imaging , Male , Middle Aged , Neural Pathways/blood supply , Neural Pathways/pathology , Neuropsychological Tests , Oxygen/blood , Psychomotor Performance , Reaction Time
6.
Vet Rec ; 173(23): 579, 2013 Dec 14.
Article in English | MEDLINE | ID: mdl-24158322

ABSTRACT

Dogs with liver disease have been shown to have increased serum C-reactive protein (CRP) concentrations. However, it is unclear whether dogs with liver disease also have increased serum haptoglobin concentrations. The aim of the study was to measure serum haptoglobin concentrations in healthy dogs, hospitalised dogs and dogs with liver diseases. Haptoglobin concentrations were measured in 30 healthy dogs, 47 hospitalised dogs with non-hepatic illness, 46 dogs with congenital portosystemic shunt (cPSS) and 11 dogs with primary hepatopathy. Haptoglobin concentrations were not significantly different between cPSS dogs with and without hepatic encephalopathy (HE), thus all cPSS dogs were considered as one group. Haptoglobin concentrations were significantly different between the remaining groups (P<0.0001). Hospitalised ill dogs had significantly higher haptoglobin concentrations than healthy dogs (P<0.001), dogs with cPSS (P<0.001) and dogs with primary hepatopathy (P<0.05). There was no significant difference between haptoglobin concentrations in healthy dogs, dogs with cPSS and dogs with primary hepatopathy. Haptoglobin concentrations were not significantly increased in dogs with liver diseases or in dogs with cPSS and HE. This is in contrast with the previously reported CRP results. This study demonstrates that liver function should be considered when interpreting haptoglobin concentrations in dogs.


Subject(s)
Dog Diseases/blood , Haptoglobins/analysis , Liver Diseases/veterinary , Animals , Case-Control Studies , Dogs , Liver Diseases/blood
9.
J Clin Pathol ; 62(6): 539-41, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19190008

ABSTRACT

BACKGROUND: The diagnosis of invasive aspergillosis (IA) remains challenging and frequently is not made until after death. Histopathological examination remains central to confirmation of diagnosis but often requires invasive procedures to obtain tissue for the examination. Detection of aspergillus DNA by quantitative PCR (qPCR) offers the potential for earlier diagnosis due to higher sensitivity, but PCR in clinical use is poorly reproducible, with different centres reporting variable results and often using different extraction and analytical methods. AIMS: To optimise the performance of aspergillus PCR as a diagnostic modality. METHODS: A rat inhalation model of invasive aspergillosis was used to optimise the methodology of diagnostic aspergillus PCR. Infected animals were terminally bled at 4 days post-infection; samples of EDTA blood, serum and the residual clot were pooled for subsequent analysis. DNA was extracted from each fraction using a variety of methods and an optimised qPCR reaction using an Aspergillus fumigatus primer set performed. RESULTS: Significantly more aspergillus DNA was detected from the clot than EDTA and serum samples. Enzymatic and mechanical pretreatment reduced the yield of fungal DNA. There was some evidence that the average Ct values were greater for the EZ1 BioRobot than the MagNA Pure automated extractor, but this did not reach statistical significance at the 5% level (p = 0.078). CONCLUSIONS: Automated extraction from the clot present in a blood sample will increase DNA yield and improve the diagnostic sensitivity of the test.


Subject(s)
Aspergillosis/diagnosis , Aspergillus fumigatus/genetics , DNA, Fungal/blood , Reverse Transcriptase Polymerase Chain Reaction/methods , Thrombosis/microbiology , Animals , Anticoagulants , Base Sequence , DNA Primers/genetics , Edetic Acid , Models, Animal , Molecular Sequence Data , Mycological Typing Techniques , Rats
11.
Blood ; 95(3): 1047-55, 2000 Feb 01.
Article in English | MEDLINE | ID: mdl-10648421

ABSTRACT

When bcl-2 is immunoprecipitated from (32)P-labeled cell extracts of all-trans retinoic acid (ATRA)-treated acute myeloblastic leukemia (AML) blasts, a phosphorylated protein of approximately 30 kd is coprecipitated. This protein has been identified as ribosomal protein S3a. The biologic effects of S3a include favoring apoptosis and enhancing the malignant phenotype. We sought to determine whether S3a, like bcl-2, influenced the response of cells to chemotherapeutic drugs and ATRA. Cell lines were studied in which S3a was genetically increased or disrupted; increased S3a was regularly associated with increased plating efficiency and increased sensitivity to either cytosine arabinoside (ara-C) or doxorubicin (DNR). S3a did not affect the sensitivity of cells to paclitaxel. Pulse exposures to either (3)HTdR or ara-C showed a greater percentage of clonogenic cells in the S phase of the cell cycle in cells with increased S3a than in controls. Cells with increased S3a responded to ATRA by increased ara-C or DNR sensitivity, whereas cells with reduced S3a protein were either protected by ATRA or not affected. We studied cryopreserved blast cells from patients with AML or chronic myelomonocytic leukemia (CMML). S3a protein levels were heterogeneous in these populations. In 32 cryopreserved blast populations, S3a levels were significantly correlated with both bcl-2 and with cell growth in culture. As in cell lines, high S3a in cryopreserved blasts was associated with ATRA-induced sensitization to ara-C. No significant association was seen between S3a levels and response to treatment.


Subject(s)
Antineoplastic Agents/pharmacology , Drug Resistance, Neoplasm/physiology , Leukemia, Myeloid, Acute/pathology , Leukemia, Myelomonocytic, Chronic/pathology , Neoplasm Proteins/physiology , Neoplastic Stem Cells/drug effects , Ribosomal Proteins/physiology , Tretinoin/pharmacology , Animals , Antibiotics, Antineoplastic/pharmacology , Antimetabolites, Antineoplastic/pharmacology , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Apoptosis , Cell Line , Cryopreservation , Cytarabine/pharmacology , DNA Replication , DNA, Neoplasm/biosynthesis , Doxorubicin/pharmacology , Gene Targeting , Humans , Leukemia, Myeloid, Acute/drug therapy , Leukemia, Myelomonocytic, Chronic/drug therapy , Neoplasm Proteins/deficiency , Neoplasm Proteins/genetics , Neoplastic Stem Cells/metabolism , Paclitaxel/pharmacology , Phosphorylation , Phosphoserine/analysis , Protein Processing, Post-Translational , Rats , Ribosomal Proteins/deficiency , Ribosomal Proteins/genetics , Tissue Preservation , Treatment Outcome
12.
Leukemia ; 12(10): 1545-52, 1998 Oct.
Article in English | MEDLINE | ID: mdl-9766498

ABSTRACT

The glutathione-depleting agent buthionine sulfoximine (BSO) was found to be toxic to some AML blast populations. This toxicity was manifested as the appearance of high levels of reactive oxygen generation in GSH-depleted cells, and later by the loss of mitochondrial membrane potential and an increase in intracellular calcium. Striking heterogeneity in BSO sensitivity was observed in a series of four human AML cell lines, and in fresh leukemic blasts obtained from eight AML patients. In some cases, toxicity was seen at BSO concentrations as low as 1 microM; approximately 100-fold less than the plasma levels achieved in patients treated with BSO as a drug resistance reversing agent. Based on these results we propose that some AML blast populations are unusually dependent on GSH-based antioxidant mechanisms, due to high intrinsic rates of reactive oxygen generation. The mitochondrial respiratory chain is the most likely source of this reactive oxygen. Because toxicity is seen at clinically achievable concentrations of BSO, this agent might have antileukemic activity in patients.


Subject(s)
Blast Crisis/pathology , Buthionine Sulfoximine/toxicity , Leukemia, Myeloid, Acute/pathology , Oxidative Stress , Reactive Oxygen Species/metabolism , Adult , Aged , Antimetabolites, Antineoplastic/toxicity , Cell Death/drug effects , Dose-Response Relationship, Drug , Female , Flow Cytometry/methods , Glutathione/metabolism , Humans , Male , Middle Aged , Tumor Cells, Cultured , Tumor Stem Cell Assay
13.
Blood ; 92(5): 1768-75, 1998 Sep 01.
Article in English | MEDLINE | ID: mdl-9716607

ABSTRACT

Serine phosphorylation of bcl-2 has been reported after treatment of cells with protein kinase C, okadaic acid, taxol, and other chemotherapeutic agents that attack microtubules. We report here that bcl-2 is phosphorylated on serine in acute myeloblastic leukemia (AML) blasts exposed to all trans retinoic acid (ATRA). Two-dimension gels (isoelectric focusing followed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis [SDS-PAGE]) disclosed a novel acidic isoform of bcl-2 in ATRA-treated blast cells from a continuous line and from two AML patients; when the cell lysates were digested with lambda-phosphatase, bcl-2 reverted to the control position, indicating that it was phosphorylated. Metabolic labeling experiments using 32Pi showed that, while control bcl-2 was labeled, incorporation was greatly increased when cells were treated with ATRA. A comparison of bcl-2 from blasts treated with ATRA or taxol showed that bcl-2 was phosphorylated on serine in cells treated with either agent; however, both qualitative and quantitative differences were seen. Qualitatively, the phosphorylated isoform from taxol-treated cells was slightly larger than the native isoform and could be distinguished on 10% to 20% SDS-polyacrylamide gradient gels, while the phosphorylated bcl-2 after ATRA ran as a single band on gradient gels at the same position as control bcl-2. Quantitatively, all bcl-2 from ATRA-treated cells was in the phosphorylated isoform, while after taxol, both phosphorylated and native bcl-2 was present; incorporation of 32Pi into bcl-2 was stimulated to greater extent in ATRA-treated compared with taxol-treated cells. We used immunoprecipitation experiments to ask if bcl-2 phosphorylated after ATRA or taxol had altered capacity to dimerize with bax. No change in dimerization was demonstrated. We conclude that: bcl-2 is phosphorylated on serine after treatment of AML blasts with ATRA; bcl-2 phosphorylation after ATRA is different from that seen after taxol; bcl-2 phosphorylated after either agent retains capacity to dimerize with bax. The ATRA or taxol-induced phosphorylation of bcl-2 can also be seen in blast cells obtained from AML patients.


Subject(s)
Leukemia, Myeloid, Acute/metabolism , Proto-Oncogene Proteins c-bcl-2/metabolism , Tretinoin/pharmacology , Dimerization , Electrophoresis, Gel, Two-Dimensional , Humans , Immunosorbent Techniques , Paclitaxel/pharmacology , Phosphoamino Acids/analysis , Phosphoric Monoester Hydrolases/metabolism , Phosphorus Radioisotopes , Phosphorylation , Phosphoserine/metabolism , Recombinant Proteins , Tumor Cells, Cultured
14.
Cancer Res ; 57(12): 2446-51, 1997 Jun 15.
Article in English | MEDLINE | ID: mdl-9192824

ABSTRACT

The mitochondrial permeability transition and oxidative stress seem to be critical alterations in cellular physiology that take place during programmed cell death. Failure to undergo apoptosis is associated with drug resistance in acute myeloid leukemia and other cancers. Therefore, it is important to establish causal relationships between the physiological changes that take place in apoptosis, because these are potential targets for novel treatment strategies to overcome this form of drug resistance. We describe the use of multilaser flow cytometry methods to make correlated measurements of mitochondrial membrane potential (MMP), the generation of reactive oxygen intermediates, the cellular content of reduced glutathione (GSH), intracellular calcium, and exposure of phosphatidylserine on the cell surface. Using these combined methods, we have mapped a "death sequence" that occurs after treatment of leukemic blasts with clinically relevant concentrations of 1-beta-D-arabinofuranosylcytosine (ara-C). Dual labeling of MMP and cellular glutathione content showed that loss of MMP, indicative of the permeability transition, took place in cells that were depleted of glutathione. The loss of MMP coincided with phosphatidylserine exposure and preceded a state of high reactive oxygen generation. Finally, there was an increase in intracellular calcium. These results demonstrate that the mitochondrial permeability transition takes place during ara-C toxicity but suggest that this occurs downstream of the loss of GSH. Thus, oxidative stress after ara-C-induced toxicity seems to be a biphasic phenomenon, with the permeability transition occurring after a depletion of GSH and preceding a state of high reactive oxygen generation.


Subject(s)
Cytarabine/pharmacology , Mitochondria/physiology , Oxidative Stress/physiology , Reactive Oxygen Species/metabolism , Calcium/metabolism , Flow Cytometry , Humans , Intracellular Membranes/physiology , Leukemia, Myeloid, Acute , Membrane Potentials , Mitochondria/drug effects , Oxidative Stress/drug effects , Permeability , Phosphatidylserines/metabolism , Time Factors , Tumor Cells, Cultured
15.
Clin Cancer Res ; 3(12 Pt 2): 2676-81, 1997 Dec.
Article in English | MEDLINE | ID: mdl-10068273

ABSTRACT

Dr. Emil J Freireich is a pioneer in the rational treatment of cancer in general and leukemia in particular. This essay in his honor suggests that the cell kill concept of chemotherapy of acute myeloblastic leukemia be extended to include two additional ideas. The first concept is that leukemic blasts, like normal hemopoietic cells, are organized in hierarchies, headed by stem cells. In both normal and leukemic hemopoiesis, killing stem cells will destroy the system; furthermore, both normal and leukemic cells respond to regulators. It follows that acute myelogenous leukemia should be considered as a dependent neoplasm. The second concept is that cell/drug interaction should be considered as two phases. The first, or proximal phase, consists of the events that lead up to injury; the second, or distal phase, comprises the responses of the cell that contribute to either progression to apoptosis or recovery. Distal responses are described briefly. Regulated drug sensitivity is presented as an example of how distal responses might be used to improve treatment.


Subject(s)
Antineoplastic Agents/therapeutic use , Leukemia/drug therapy , Leukemia/pathology , Models, Biological , Stem Cells/pathology , Blast Crisis/drug therapy , Blast Crisis/pathology , Cell Death , History, 20th Century , Humans , Leukemia/genetics , Leukemia, Myeloid, Acute/drug therapy , Leukemia, Myeloid, Acute/pathology , Oncogenes , Probability
16.
Leukemia ; 10(12): 1925-9, 1996 Dec.
Article in English | MEDLINE | ID: mdl-8946932

ABSTRACT

The sensitivity of AML blast stem cells can be measured in cell culture, using a clonogenic assay to determine survival after each of a graded series of drug concentrations. For cytosine arabinoside, the dose-response curve is a simple negative exponential that can be described by a D10 value, a measure of slope. This D10 value can be affected by regulatory molecules added to the cultures. All-trans retinoic acid (ATRA) usually sensitizes cells, while hydrocortisone (HC) is protective. Growth factor responsive cells are more Ara-C sensitive in G-CSF than in GM-CSF or IL-3. The proto-oncogene bcl-2 may be part of the mechanism by which drug sensitivity is regulated. Previous work has shown that ATRA decreases bcl-2 RNA expression and the half-life of the protein; in contrast, the protein from cells treated with HC is more stable than controls. Growth factors were not shown to change either expression of bcl-2 RNA or the stability of its protein. In this paper, we describe experiments where OCI/AML-1 cells were grown in G-CSF and then transferred to medium containing both G-CSF and the GM-CSF-IL-3 fusion protein pIXY. Steady-state levels of bcl-2 protein were measured by Western blot and synthesis by incorporation of 35S methionine into protein. We observed that both measures doubled within 12-24 h after transfer from G-CSF in G-CSF with pIXY, but promptly returned to the previous state when pIXY was withdrawn. We conclude that growth factors regulate that activity of bcl-2 post-transcriptionally by altering the rate of synthesis of the protein.


Subject(s)
Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology , Interleukin-3/pharmacology , Leukemia, Myeloid/metabolism , Proto-Oncogene Proteins c-bcl-2/biosynthesis , Antimetabolites, Antineoplastic/pharmacology , Cytarabine/pharmacology , Drug Resistance, Neoplasm , Drug Screening Assays, Antitumor , Humans , Leukemia, Myeloid/drug therapy , Proto-Oncogene Mas , Recombinant Fusion Proteins/pharmacology , Tumor Cells, Cultured/drug effects
17.
Br J Haematol ; 95(2): 354-63, 1996 Nov.
Article in English | MEDLINE | ID: mdl-8904892

ABSTRACT

Paclitaxel dose responses in culture have been investigated alone and in association with cytosine arabinoside (ARA-C) and all-trans retinoic acid (ATRA), with the objective of identifying a role for paclitaxel in the treatment of acute myeloblastic leukaemia (AML). Initial studies were done to determine if paclitaxel dose responses of AML blast cell precursors were altered by regulatory compounds known to modify the dose responses of ARA-C. In contrast to ARA-C, paclitaxel dose responses were independent of cell culture method, the growth factors G-CSF and GM-CSF, and the ligands all-trans retinoic acid (ATRA) and hydrocortisone. Most blast cell populations were sensitive to paclitaxel; compared with normal marrow progenitors the dose responses were markedly heterogenous with some more, and others less, sensitive. Remission marrow progenitor paclitaxel responses resembled those of AML blasts in heterogeneity. The cell culture model tested the effect of pacliataxel and ATRA on the ARA-C dose responses of OCI/ AML-5; paclitaxel exposure was either before or after ARA-C to test for an effect of schedule; ATRA was added to the MEC cultures after paclitaxel and ARA-C. Repeat experiments were done to test three dose levels each of paclitaxel and ATRA. When paclitaxel was given after ARA-C, synergism was found for all but one of the dose combinations tested; only three examples of synergy were seen when paclitaxel preceded ARA-C. The studies justify trials combining ARA-C, paclitaxel and ATRA using a schedule suggested by the cell culture findings.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Leukemia, Myeloid, Acute/drug therapy , Adult , Aged , Cell Division/drug effects , Cytarabine/administration & dosage , Dose-Response Relationship, Drug , Drug Synergism , Female , Granulocyte Colony-Stimulating Factor/pharmacology , Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology , Hematopoietic Stem Cells/pathology , Humans , Leukemia, Myeloid, Acute/pathology , Male , Middle Aged , Paclitaxel/administration & dosage , Tretinoin/administration & dosage , Tumor Cells, Cultured
18.
Leukemia ; 10(7): 1143-9, 1996 Jul.
Article in English | MEDLINE | ID: mdl-8683994

ABSTRACT

Cytosine arabinoside is usually considered to be lethal by incorporation into DNA followed by chain termination. Recently, we have reported that the radical scavenger N-acetyl-cysteine (NAC) protects cultured clonogenic AML blast cells from the lethal affects of Ara-C if given before the drug. This observation provides indirect evidence that toxic reactive oxygen intermediates (ROI) are generated in AML blast cells following Ara-C-induced damage to DNA. In the present paper we present evidence in support of this hypothesis. Using flow cytometry and multiple fluorescent probes for live cell function, we have mapped a sequence of discrete stages that occur during Ara-C cytotoxicity. An early event was the increased generation of ROI. Initially this oxidative stress was countered by an increase in the cellular content of reduced glutathione (GSH), but cells then underwent an abrupt transition to a state characterized by low GSH and very high ROI generation indicative of collapse of cellular redox balance. Next, the capacity to maintain low intracellular ionized calcium was lost, probably due to lipid peroxidation at membrane sites of calcium regulation. Finally, surface membrane integrity was lost. Concurrent measurements of clonogenic cell survival insured the relevance of these flow cytometry measurements to the stem cell population. We used OCI/AML-2 cells transfected with bcl-2 to look for the place in this sequence where bcl-2 protein protects cells against apoptosis; bcl-2 transfectants showed an increase in ROI generation similar to controls, but were able to maintain GSH levels in the face of this oxidative stress. We conclude that oxidative stress plays a major role in Ara-C toxicity, and that bcl-2 protein protects cells by maintaining cellular redox balance in a reducing state. These studies complement previous work showing how regulators of AML growth affect the sensitivity of blast cells to Ara-C by changing the concentration or stability of bcl-2 protein.


Subject(s)
Antimetabolites, Antineoplastic/pharmacology , Blast Crisis/pathology , Cytarabine/pharmacology , Leukemia, Myeloid, Acute/pathology , Proto-Oncogene Proteins/physiology , Reactive Oxygen Species/metabolism , Apoptosis/drug effects , Blast Crisis/metabolism , Calcium/metabolism , Cell Membrane/metabolism , Flow Cytometry , Glutathione/metabolism , Humans , Leukemia, Myeloid, Acute/metabolism , Lipid Peroxidation , Neoplastic Stem Cells/drug effects , Neoplastic Stem Cells/metabolism , Neoplastic Stem Cells/pathology , Oxidation-Reduction , Oxidative Stress , Proto-Oncogene Proteins c-bcl-2 , Transfection , Tumor Cells, Cultured/drug effects , Tumor Cells, Cultured/metabolism , Tumor Cells, Cultured/pathology , Tumor Stem Cell Assay
19.
Leukemia ; 10(3): 410-6, 1996 Mar.
Article in English | MEDLINE | ID: mdl-8642855

ABSTRACT

The blast stem cells of acute myeloblastic leukemia become more sensitive in culture to the chemotherapeutic agents cytosine arabinoside (Ara-C) and daunorubicin (DNR) when exposed to all-trans retinoic acid (ATRA) after drug. We have proposed that down regulation of bcl-2 by ATRA is part of the mechanism of sensitization. The hypothesis is based on reduced expression of bcl-2 mRNA, as seen in Northern blots, after ATRA. Nuclear run on experiments, however, failed to account completely for the effect at the transcriptional level. Accordingly, we looked for post-transcriptional effects of ATRA on bcl-2, using metabolic labelling of the protein to measure stability. We found that the half-life of bcl-2 protein is markedly shortened after treatment with ATRA. Hydrocortisone (HC) protects cells against the toxic effects of Ara-C or DNR when given before drug. HC does not alter bcl-2 expression at the level of mRNA; however, metabolic labelling shows that newly synthesized bcl-2 protein is stabilized in blast cells treated with HC. Response to Ara-C by growth factor responsive blast cells is influenced by the factor in the cultures; cells are more sensitive in cultures with G-CSF and less sensitive when GM-CSF is present. We compared two blast cell lines, OCI/AML-5, primarily responsive to GM-CSF, and OCI/AML-10, primarily responsive to G-CSF. Growth factor did not influence the stability of bcl-2 protein in either line. In contrast, Western blots showed that the amount of bcl-2 protein was greater in cultures with GM-CSF or GM-CSF in combination with G-CSF than in cultures with G-CSF or no added factor. This pattern was seen regardless of the mitogenic response to G-CSF or GM-CSF. We interpret our findings as indicating that bcl-2 protein is transcriptionally activated; that the stability of the protein is decreased after ATRA and increased after HC; that the amount of bcl-2 protein is greater in cultures with GM-CSF than in cultures with G-CSF, regardless of which factor gives the greater mitogenic response. We propose that these post-transcriptional modifications of transcriptionally activated bcl-2 account, in part, for the regulation of drug sensitivity by ATRA, HC and growth factors.


Subject(s)
Leukemia, Myeloid, Acute/genetics , Proto-Oncogene Proteins/genetics , Transcription, Genetic/drug effects , Anti-Inflammatory Agents/pharmacology , Antibiotics, Antineoplastic/pharmacology , Antimetabolites, Antineoplastic/pharmacology , Blotting, Northern , Blotting, Western , Cytarabine/pharmacology , Daunorubicin/pharmacology , Down-Regulation/drug effects , Gene Expression Regulation, Leukemic/drug effects , Granulocyte Colony-Stimulating Factor/pharmacology , Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology , Humans , Hydrocortisone/pharmacology , Leukemia, Myeloid, Acute/drug therapy , Leukemia, Myeloid, Acute/metabolism , Proto-Oncogene Proteins/metabolism , Proto-Oncogene Proteins c-bcl-2 , RNA, Messenger/metabolism , Remission Induction , Transcriptional Activation/drug effects , Tretinoin/pharmacology , Tumor Cells, Cultured/drug effects , Tumor Cells, Cultured/metabolism
20.
Hematopathol Mol Hematol ; 10(3): 111-22, 1996.
Article in English | MEDLINE | ID: mdl-8878730

ABSTRACT

Growth factors are commonly included in protocols for the treatment of acute myeloblastic leukemia (AML). Because the response of blast stem cells in culture to growth factors might influence the contribution of factor to clinical outcome, we studied 42 patients with AML or severe myelodysplasia. Peripheral blood blast cells were cultured in a clonogenic assay at three cell concentrations and with the following combinations of growth factors: no added growth factor (NF), G-CSF, GM-CSF, Kit ligand (KL), G-CSF + KL, GM-CSF + KL, and G-CSF + GM-CSF + KL. The slope of the line relating cell number plated to colony formation was calculated by least squares. The slopes were used to form three equally sized groups of patients. Marked heterogeneity was found in response of the blast populations to factor. A few general conclusions emerged: (1) autonomous blast populations are very rare; (2) although usually a population responds better to one of the growth factors than to others, seldom is the response exclusively to one factor; (3) when more than one factor is included in the cultures, synergism is usually seen. Significant associations were seen between successful remission induction for low slope values in cultures with NF or KL alone. For remission, but not survival, associations were found with intermediate values of slope in cultures with G-CSF + KL and GM-CSF + KL. We conclude that measurements of growth factor response are feasible and yield clinically useful data.


Subject(s)
Granulocyte Colony-Stimulating Factor/pharmacology , Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology , Hematopoietic Stem Cells/pathology , Leukemia, Myeloid, Acute/blood , Stem Cell Factor/pharmacology , Adult , Aged , Aged, 80 and over , Cell Division/drug effects , Drug Synergism , Female , Hematopoietic Stem Cells/drug effects , Humans , Leukemia, Myeloid, Acute/pathology , Male , Middle Aged , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL
...